Listed TSX, Symbol:  CNJ

TORONTO & WINNIPEG, June 10, 2011 /CNW/ - Cangene Corporation today announces that it intends to host a conference call on Tuesday, June 14, 2011 at 11:00 a.m. Eastern, to discuss its financial results for the third quarter of fiscal 2011, ended April 30, 2011. The Company intends to disclose its financial results via news release after market close on Monday, June 13, 2011.

To access the conference call by telephone, dial 1-888-231-8191 or 647-427-7450. The conference call will be archived for replay until Tuesday, June 21, 2011, at midnight. To access the archived conference call, dial 1-800-642-1687 or 416-849-0833 and enter the reservation number 74278534 followed by the number sign.

A live audio webcast of the conference call will be available at www.cangene.com and www.newswire.ca. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web sites for 90 days.

About Cangene Corporation
Cangene is one of Canada's largest and earliest biopharmaceutical companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba. Cangene has approximately 700 employees in six locations across North America and its products are sold worldwide. It operates manufacturing facilities in Winnipeg, Manitoba and Baltimore, Maryland. Cangene operates three U.S. and one Canadian plasma-collection facilities branded as Cangene Plasma Resources (www.cangeneplasma.com). In addition, it has a regulatory affairs, sales and corporate communications office in Toronto, Ontario.

Cangene is focused on developing therapeutics for infectious diseases, and the Company uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. Cangene has four FDA and/or Health Canada-approved hyperimmune products. In addition, the Company has several more products in development at various stages. Three of Cangene's products have been accepted into the U.S. Strategic National Stockpile—botulism antitoxin (investigational product), anthrax immune globulin (investigational product) and a vaccinia immune globulin, a product that may be used to counteract certain complications that may arise from smallpox vaccination. Cangene's wholly-owned subsidiary, Cangene bioPharma, Inc., is based in Baltimore, Maryland and includes its U.S. commercial sales and marketing office as well as a significant contract-manufacturing business (www.cangenebiopharma.com). Cangene's website, www.cangene.com, includes product and investor information, including past news releases.